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Abstract Residual excessive sleepiness (ES) and impaired
cognition can occur despite effective and regular nasal
continuous positive airway pressure (nCPAP) therapy in
some patients with obstructive sleep apnea (OSA). A
pooled analysis of two 12-week, randomized, double-blind
studies in nCPAP-adherent patients with ES associated with
OSA evaluated the effect of armodafinil on wakefulness
and cognition. Three hundred and ninety-one patients
received armodafinil (150 or 250 mg) and 260 patients
received placebo once daily for 12 weeks. Efficacy assess-
ments included the Maintenance of Wakefulness Test
(MWT), Cognitive Drug Research cognitive performance
battery, Epworth Sleepiness Scale, and Brief Fatigue
Inventory. Adverse events were monitored. Armodafinil
increased mean MWT sleep latency from baseline to final
visit by 2.0 min vs a decrease of 1.5 min with placebo (P<
0.0001). Compared with placebo, armodafinil significantly
improved quality of episodic secondary memory (P<0.05)
and patients’ ability to engage in activities of daily living
(P<0.0001) and reduced fatigue (P<0.01). The most
common adverse events were headache, nausea, and
insomnia. Armodafinil did not adversely affect desired
nighttime sleep, and nCPAP use remained high (approxi-
mately 7 h/night). Adjunct treatment with armodafinil
significantly improved wakefulness, long-term memory,
and patients’ ability to engage in activities of daily living
in nCPAP-adherent individuals with ES associated with
OSA. Armodafinil also reduced patient-reported fatigue and
was well tolerated.
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Introduction
Obstructive sleep apnea (OSA) syndrome includes exces-
sive sleepiness (ES), fatigue, sleep fragmentation, impaired
alertness, cognitive dysfunction, and mood disturbances [1,
2]. OSA is typically characterized by recurrent complete or
partial airway collapse during sleep, resulting in frequent
apnea and hypopneic events lasting at least 10 s [1].
Although the reported prevalence of OSA in the general
population varies as a function of diagnostic criteria [2],
OSA syndrome has been estimated to occur in 4 and 2% of
middle-aged North American men and women, respectively
[3]. OSA can lead to serious medical, social, and public
safety consequences, and patients are at an increased risk
for cardiovascular disease [4] and motor vehicle and
occupational accidents [5, 6]. Quality of life and social
functioning are also significantly impaired in this patient
population [7, 8]. Fatigue, in particular, can contribute to
reduced quality of life [1, 9]; thus, the assessment of
patient-rated fatigue is an important outcome to evaluate
and monitor in patients with OSA.
Nasal continuous positive airway pressure (nCPAP)
therapy is the recommended standard of care for treating
patients with moderate to severe OSA [10]. In a compre-
hensive review of 36 clinical studies, nCPAP therapy was
shown to effectively reduce objective and subjective
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measures of sleepiness and improve quality of life in
patients with moderate and severe OSA [11]. However,
despite receiving adequate nCPAP therapy, half of patients
with OSA still experience residual ES as measured by
objective assessments as well as impairments in mood or
cognition [12–18]. Cognitive impairment in patients with
OSA is characterized by deficits in attention, learning and
memory, and executive function (planning and problem
solving) and may persist despite nCPAP therapy [12, 15–
17]. A review of the literature suggests that while nCPAP
therapy can substantially improve quality of life for patients
with OSA, it has a smaller effect on improving cognitive
performance [7].
Modafinil, a racemic mixture consisting of equal amounts
of R- and S-enantiomers, has been shown to improve
wakefulness in patients with OSA who experience residual
ES despite regular nCPAP use [19, 20]. Pharmacokinetic
studies have shown that the half-life of R-modafinil (10–
14 h) is significantly longer than the half-life of S-modafinil
(3–4 h) [21–23]. Armodafinil has higher plasma concen-
trations later in the day compared to modafinil on a
“milligram-to-milligram” basis and improves healthy sub-
jects’ wakefulness and ability to sustain attention for a longer
period of time compared with modafinil [24]. Armodafinil
has also recently been shown to improve wakefulness in
patients with ES associated with narcolepsy in a 12-week
double-blind, placebo-controlled study [25].
Recent findings from two 12-week, double-blind, placebo-
controlled studies of similar design indicate that armodafinil
improved wakefulness and overall clinical condition in
nCPAP-adherent patients with OSA and residual ES [26,
27]. In the present pooled analysis of the two OSA studies
[26, 27], the effects on wakefulness, cognition, and fatigue
and the safety and tolerability of armodafinil compared with
placebo were evaluated in OSA patients adherent to nCPAP
therapy.
Materials and methods
Study design and procedures
Data from two 12-week, multicenter, double-blind, placebo-
controlled, parallel-group clinical studies were pooled for
analysis. The pooling of these data was based on similarities
in patient population, study design, and treatment duration in
the two studies [26, 27]. One study was conducted in 36
centers across the USA, Australia, Russia, Germany, and
France [26], and the other study was conducted in 37
centers across the USA and Canada [27]. The study
protocols were approved by an Independent Ethics Com-
mittee or Institutional Review Board at each center. Both
studies were conducted in accordance with the Good
Clinical Practice: Consolidated Guideline [28] and national
and local laws and regulations.
Patients were randomized to receive armodafinil 150 mg
(n=129) or placebo (n=130) daily in the first study [26]
and armodafinil 150 (n=131) or 250 mg/day (n=131), or
placebo (n=130) in the second study [27]. Study drugs
were initiated with a dose of 50 mg/day on day 1 and then
increased in increments of 50 mg starting on day 2 and
every 2 days thereafter until the assigned dose was reached
(i.e., 150 mg/day on day 4 for both studies or 250 mg/day
on day 8 for the second study). The study drugs were taken
once daily in the morning (before 08:00 and approximately
30 min before breakfast). Monitoring of patients’ compli-
ance with study drug administration was the responsibility
of the investigator at each center and was assessed by
completed study drug accountability records and reviews of
patient diaries. nCPAP use at home was also monitored
objectively by investigators at each visit to the study center,
using the REMstar® Auto CPAP System (Respironics,
Murrysville, PA). The REMstar Auto CPAP System was
used in CPAP mode.
Patient selection criteria
Methods for selecting patients in both studies have been
described previously [26, 27]. Men and women 18 to
65 years of age with a current diagnosis of OSA as defined
by the International Classification of Sleep Disorders [1]
were included in both studies. Patients were at least
moderately ill (Clinical Global Impression of Severity of
Illness rating greater than or equal to 4) [29] and had a
complaint of ES. Patients were eligible if ES was
determined to be pathological, based on an Epworth
Sleepiness Scale (ESS) score greater than or equal to 10
[30]. All patients were receiving stable (greater than or
equal to 4 weeks) and effective nCPAP therapy on a regular
basis (greater than or equal to 4 h per night on greater than
or equal to 70% of nights) during the 2-week evaluation
period. The CPAP use was monitored using the REMstar
Auto CPAP System. Effectiveness of therapy was deter-
mined by an apnea–hypopnea index (AHI) less than or
equal to ten events per hour on nighttime polysomnography
(PSG).
Patient exclusion criteria
Patients were excluded if they had any of the following: a
diagnosis of a sleep disorder other than OSA, symptoms of
ES associated with a clinically significant uncontrolled
medical or psychiatric condition as determined by the
investigator, any disorder that might interfere with drug
absorption, distribution, metabolism, or excretion, a history
of drug or alcohol abuse, as determined by the Diagnostic
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and Statistical Manual of Mental Disorders IV criteria [31]
or by a positive result from the urine drug screen given at
screening and again at the final visit, caffeine consumption
greater than 600 mg/day, or a clinically significant
sensitivity to central nervous system stimulants or modafinil.
Women who were pregnant or breast feeding were also
excluded. The use of any substance that could affect
wakefulness or sleepiness (e.g., modafinil, sodium oxybate,
melatonin, lithium, St. John’s wort, methylphenidate,
amphetamines, pemoline, antipsychotic agents, benzodiaze-
pines, zolpidem, anticonvulsants, or barbiturates), use of
other excluded agents (e.g., monoamine oxidase inhibitors,
anticoagulants), use of clinically significant amounts of
nonprescription drugs within 7 days of screening, and use of
investigational drugs within 1 month of screening was
prohibited. All patients provided written informed consent




Efficacy assessments were performed for both studies at
baseline and weeks 4, 8, and 12. The primary efficacy
variables in the two individual studies were the change
from baseline to final visit (week 12 or last postbaseline
measurement) in mean Maintenance of Wakefulness Test
(MWT) [32, 33] sleep latency averaged across the first four
tests and the proportion of patients with at least minimal
improvement on the Clinical Global Impression of Change
(CGI-C) [29]. The MWT was conducted as six separate
30-min sessions at 09:00, 11:00, 13:00, 15:00, 17:00, and
19:00. Sleep latency was defined as the time to onset of the
first of three consecutive epochs of stage 1 sleep or the time
to onset of any epoch of stages 2, 3, and 4 sleep or rapid
eye movement sleep [34]. Sleep latencies were averaged
across the first four tests (09:00, 11:00, 13:00, 15:00) and
the last three tests (15:00, 17:00, 19:00) to distinguish
between early- and late-day effects, respectively. The
proportion of patients with at least a minimal improvement
on the CGI-C was assessed to determine patients’ overall
clinical improvement in the individual studies; however,
these data were not poolable for this analysis because of a
substantial difference in the percentage of responders to
placebo between the two studies.
The Cognitive Drug Research (CDR) battery of tests [35,
36] was administered by computer as six separate 25-min
sessions conducted at 09:30, 11:30, 13:30, 15:30, 17:30,
and 19:30. The CDR battery includes five memory tests
(immediate word recall, delayed word recall, numeric
working memory, word recognition, and picture recogni-
tion) and three attention tests (simple reaction time, choice
reaction time, and digit vigilance). Two composite factors
are derived from the memory tests in the CDR: quality of
episodic secondary memory, a measure of long-term
memory that measures the ability to recall verbal and
visual information, and speed of memory, which assesses
the time it takes to decide whether information is held in
memory. Two composite factors are derived from the CDR
for attention: power of attention, which measures the ability
to focus attention and avoid distraction (concentration), and
continuity of attention, which measures the ability to
sustain attention (vigilance). Similar to the MWT, the
CDR scores were averaged across the first four test sessions
(09:30, 11:30, 13:30, 15:30) and the last three test sessions
(15:30, 17:30, 19:30) to assess cognitive effects on early-
and late-day measurements.
The patients’ ability to engage in daily activities was
assessed at each visit by the ESS [30]. ESS total scores
range from 0 to 24, with higher scores indicating greater
sleepiness. An ESS score greater than or equal to 10
indicates pathological sleepiness [30]. The severity and
impact of patient-rated fatigue on daily functioning were
assessed at each visit by the nine-item Brief Fatigue
Inventory (BFI) [37] and were based on changes in global
fatigue (average of all nine questions) and worst fatigue in
the past 24 h (item 3). The rating scale for the BFI ranges
from 0 (no fatigue) to 10 (as bad as you can imagine). A
score of greater than or equal to 7 for either global fatigue
or worst fatigue in the past 24 h is indicative of severe
fatigue. Both the ESS and BFI were administered before the
first MWT session (09:00) at each visit.
Safety and tolerability assessments
Adverse events were monitored and recorded by the study
investigators at each center throughout both studies.
Clinical laboratory tests (blood chemistry, hematology,
urinalysis), vital signs (resting heart rate and systolic and
diastolic blood pressure 3 and 13 h postadministration), and
electrocardiograms were obtained at screening, baseline,
and weeks 4, 8, and 12. Physical examinations were
performed at baseline and week 12. Patients’ use of nCPAP
was monitored at least 2 weeks before baseline and
throughout both studies using the Respironics REMstar
Auto CPAP system. Effect on nighttime sleep was
determined by PSG, which was performed the night
immediately after the measurement of daytime MWT
during the second screening visit and the final visit. The
PSG was conducted for 8 h, starting within 30 min of the
patient’s usual bedtime but not earlier than 21:30.
Clinically significant elevations in resting systolic and
diastolic blood pressure were defined a priori as greater
than or equal to 140 mmHg with an increase of greater than
or equal to 10% and greater than or equal to 90 mmHg with
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an increase of greater than or equal to 10%, respectively.
Patients with worsening hypertension included those who
had a history of hypertension at baseline and who started
new antihypertensive medication and/or increased the dose
of previously used antihypertensive medication during the
studies. Patients with newly diagnosed hypertension in-
cluded those who had no history of hypertension at baseline
and who started antihypertensive medication during the
studies. Patients at risk for hypertension included those who
had at least two clinically significant elevations in blood
pressure readings between baseline and final visit.
Statistical analysis
Descriptive statistics were used to summarize continuous
and categorical demographic variables. Efficacy assess-
ments were analyzed at weeks 4, 8, and 12 using observed
cases and at final visit (week 12 or last postbaseline
measurement) using the last observation carried forward
approach. Efficacy analyses included randomized patients
who received at least one dose of study drug and had a
baseline measurement with at least one postbaseline
measurement on the MWT and CGI-C. Safety and
tolerability analyses included all randomized patients who
received at least one dose of study drug. All efficacy
assessments were analyzed by analysis of variance
(ANOVA) with treatment and study as factors. Tests of
poolability for all continuous efficacy variables across the
two studies were conducted using an ANOVA with
treatment and study and treatment by study interaction as
factors. Vital signs and data from nighttime PSG were
analyzed by Wilcoxon rank-sum test. For nCPAP use, the
change from baseline to on-treatment values was analyzed
using one-way ANOVA. All statistical tests were two-
tailed, and the 5% level of significance was used.
Results
Patient demographics and disease characteristics
Of 658 patients randomized, 651 were included in the
safety analysis, and 601 were evaluable for efficacy
(Fig. 1). Patient demographics and disease characteristics
for all patients in the safety analyses are summarized in
Table 1. The mean body mass index was 36.6 kg/m2.
Patients reported high nightly nCPAP usage (mean [SD]
hours of nightly use, armodafinil 6.9 [1.2] h; placebo 6.9
[1.0] h). The nCPAP therapy was effective, as shown by
mean (SD) AHI values of 1.5 (3.3) and 1.2 (2.1) events/h in
the armodafinil and placebo groups, respectively. Overall,
41% of patients had a history of hypertension at baseline.
Effects on wakefulness
Mean (SD) sleep latency at baseline across the first four
MWTs (09:00, 11:00, 13:00, 15:00) was 22.8 (8.4) and 23.2
(7.9) min for the armodafinil and placebo groups, respec-
tively. At all study visits, armodafinil significantly im-
proved mean sleep latency across the first four MWTs
Fig. 1 Patient disposition
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compared with placebo (Fig. 2a). The mean change from
baseline in sleep latency at final visit was 2.0 min for the
armodafinil group compared with −1.5 min for the placebo
group (P<0.0001).
Armodafinil also improved patients’ ability to maintain
late-day wakefulness (MWTs at 15:00, 17:00, 19:00)
compared with placebo (Fig. 2b). Mean (SD) sleep latency
at baseline across the last three MWTs was 24.4 (7.8) and
24.6 (7.4) min for the armodafinil and placebo groups,
respectively. The mean change from baseline in sleep
latency at final visit was 1.1 min for the armodafinil group
compared with −0.3 min for the placebo group (P<0.05).
Effects on memory and attention
Compared with placebo, armodafinil significantly improved
the quality of episodic secondary memory across the first four
tests (09:30, 11:30, 13:30, 15:30) at all study visits (P<0.05;
Fig. 3a). The mean (SD) change from baseline in quality of
episodic secondary memory at final visit was 10.2 (31.7) U
for the armodafinil group compared with −0.7 (46.3) U for
the placebo group (P<0.01). Differences between the
treatment groups did not achieve statistical significance at
the final visit for speed of memory, power of attention, or
continuity of attention across the first four tests.
Across the later three tests of the day (15:30, 17:30,
19:30), the difference in the quality of episodic secondary
memory was statistically significant at week 8 for armodafinil
compared with placebo (P=0.011; Fig. 3b), with a trend
toward significance at week 12 (P=0.081). The difference
between treatment groups was not statistically significant at
the final visit for the quality of episodic secondary memory.
There were no significant changes from baseline to final visit
between the armodafinil and placebo groups for speed of
memory, power of attention, or continuity of attention across
the last three tests.
Effects on patients’ ability to engage in activities
The mean (SD) ESS scores were high at baseline (15.4
[3.5] and 15.9 [3.5] for the armodafinil and placebo groups,
respectively), despite the high nCPAP use as shown in
Table 1. Compared with placebo, treatment with armodafinil
significantly improved patients’ ability to engage in activities
of daily living (ESS) at all visits (P<0.0001; Fig. 4). Nearly
half of all patients (49%) in the armodafinil group responded
to treatment (total ESS score less than 10 at final visit)
compared with 26% in the placebo group.






Mean (SD) 49.7 (9.0) 50.3 (9.1)
Sex, n (%)
Men 283 (72) 183 (70)
Women 108 (28) 77 (30)
Race, n (%)
White 327 (84) 224 (86)
Black 36 (9) 21 (8)
Asian 6 (2) 3 (1)
Other 22 (6) 11 (4)
Missing 0 1 (<1)
Weight (kg)
Mean (SD) 110.4 (24.6) 111.2 (23.7)
BMI (kg/m2)
Mean (SD) 36.4 (8.0) 36.9 (7.5)
CGI-S, n (%)
Moderately ill 219 (56) 138 (53)
Markedly, severely, or extremely ill 172 (44) 122 (47)
nCPAP (h)
Mean (SD) 6.9 (1.2) 6.9 (1.0)
AHI
Mean (SD) 1.5 (3.3) 1.2 (2.1)
History of hypertension
n (%) 159 (41) 108 (42)
AHI Apnea–hypopnea index, BMI body mass index, CGI-S Clinical
Global Impression of Severity of Illness, nCPAP nasal continuous
positive airway pressure
Fig. 2 Mean (SEM) change from baseline in sleep latency from the
Maintenance of Wakefulness Test (MWT). a Sleep latencies averaged
across the first four tests (09:00–15:00). b Sleep latencies averaged
across the last three tests (15:00–19:00)
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Effects on fatigue
The mean (SD) scores for global fatigue from the BFI at
baseline were 4.8 (1.9) and 4.9 (1.9) for the armodafinil and
placebo groups, respectively. Armodafinil significantly
improved global fatigue at all visits compared with placebo
(P<0.01; Fig. 5a). Mean scores for worst fatigue in the past
24 h from the BFI at baseline were nearly identical for the
armodafinil and placebo groups (7.2 [2.0] and 7.3 [2.0],
respectively) and indicated severe fatigue (score greater
than or equal to 7). Armodafinil significantly improved
scores for worst fatigue in the past 24 h at weeks 4 and 12
and at the final visit (P<0.05 vs placebo; Fig. 5b), with a
trend toward significance at week 8 (P=0.056 vs placebo).
Safety and tolerability
Armodafinil was well tolerated, with a low incidence of
adverse events, most of which were mild to moderate in
nature. Headache was the most commonly reported adverse
event, defined as occurring in greater than or equal to 5% in
either group (Table 2). Serious adverse events were
considered by the investigator unlikely to be or not related
to armodafinil (ulcerative colitis, n=1; migraine, n=1;
worsening of Axis II disorder and mood disorder, n=1;
duodenal ulcer hemorrhage, n=1). One serious adverse
event was reported in the placebo group (gastroesophageal
reflux disease). The most frequently occurring adverse
Fig. 4 Mean (SEM) change from baseline in Epworth Sleepiness
Scale total score
Fig. 5 Mean (SEM) change from baseline in fatigue. a Global
fatigue. b Worst fatigue in the past 24 h. BFI Brief Fatigue Inventory
Fig. 3 Mean (SEM) change from baseline in quality of episodic
secondary memory. a Scores averaged across the first four tests
(09:30–15:30). b Scores averaged across last three tests (15:30–19:30)
Table 2 Adverse events occurring in ≥5% of patients
Adverse event, n (%) Armodafinil (n=391) Placebo (n=260)
Headache 65 (17) 20 (8)
Nausea 22 (6) 10 (4)
Insomnia 22 (6) 3 (1)
Dizziness 19 (5) 4 (2)
Anxiety 20 (5) 2 (<1)
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events that led to discontinuation among patients receiving
armodafinil were headache (n=5) and nausea (n=4).
There were no clinically significant changes from
baseline to final visit in either the armodafinil group or
the placebo group for laboratory values, electrocardiogram
parameters, or physical examinations. There were also no
meaningful changes (clinical or statistical) from baseline to
final visit for systolic blood pressure (0.2 [14.2] mmHg for
armodafinil vs −1.0 [14.6] mmHg for placebo), diastolic
blood pressure (0.3 [9.3] mmHg for armodafinil vs −1.0
[10.0] mmHg for placebo), and heart rate (2.3 [9.6] bpm for
armodafinil vs 1.4 [9.6] bpm for placebo).
The incidence of patients with newly diagnosed hyperten-
sion was less than 1% in the armodafinil group and less than
1% in the placebo group. The proportion of patients at risk for
hypertension was similar for both treatment groups (18% of
391 patients, armodafinil group; 16% of 260 patients,
placebo group). The incidence of patients with worsening
hypertension was 3% of 391 patients in the armodafinil group
and 2% of 260 patients in the placebo group.
nCPAP use remained high (approximately 7 h/night)
throughout both of the studies. The duration of nCPAP use
at final visit was reduced from baseline by a mean (SD) of
−0.3 (0.7) h with armodafinil compared with −0.1 (0.6) h
with placebo (a between-group difference of about 12 min;
P<0.0001). At final visit, AHI values remained low and
were comparable between the armodafinil and placebo
groups (P>0.05 vs placebo). In addition, there were no
significant changes from baseline in nocturnal PSG sleep
variables between the armodafinil and placebo groups
(P>0.05; Table 3).
Discussion
Recognizing and effectively managing ES in patients with
OSA is essential for clinicians because of the profound
impact that ES has on the patients, their families and
coworkers, and the general public (e.g., increased risk of
traffic accidents) [4–6]. Without appropriate treatment, ES
adversely affects cognitive [15, 17], occupational [6], and
social functioning [8]. Several studies evaluated in a
comprehensive review [11] have shown that there is general
improvement in wakefulness with nCPAP therapy, espe-
cially in patients with more severe OSA. Nonetheless,
residual ES can persist even after effective nCPAP
treatment [18], suggesting that there is need for adjunctive
therapy to treat ES in these patients.
The present study re-evaluates the findings from two
separate studies on the effects of armodafinil in patients
with refractory ES associated with OSA and provides
additional information regarding secondary analyses, for
which the individual studies may not have had adequate
statistical power. In the individual studies [26, 27],
armodafinil was shown to significantly improve daytime
mean sleep latency across the first four tests on the MWT
and overall clinical condition as assessed by the CGI-C. In
the pooled analysis, armodafinil significantly improved
patients’ ability to sustain wakefulness as objectively
assessed by the MWT. Improvements in mean sleep latency
were observed at the first visit at week 4 and were
maintained throughout the remainder of the study. The lack
of a consistent effect of armodafinil on wakefulness across
the last three MWTs (15:00, 17:00, 19:00) likely reflects the
high mean sleep latency (approximately 24.5 min) at these
times. Behavioral effects, causing poorer performance on
the last test of the day, and high intertest variability in sleep
latency may have also contributed to this finding [38].
The individual studies also included the clinician’s subjec-
tive assessment of treatment effect on ES, the CGI-C. Data for
the CGI-C, however, were not poolable for this analysis
because of substantial differences in the proportion of patients
considered responders to placebo between the two studies. In
the individual studies, the proportion of patients considered
Table 3 Nocturnal polysomnography parametersa
Variable (units), mean (SD) Armodafinil (n=391) Placebo (n=260)
Baseline Final Visit Baseline Final Visit
Latency to persistent sleep (min) 22.3 (26.9) 19.6 (20.5) 21.3 (24.0) 20.8 (21.4)
Number of arousals, n 20.0 (11.3) 18.5 (10.2) 18.7 (9.7) 18.4 (10.4)
Number of awakenings, n 8.8 (4.7) 9.2 (5.3) 8.7 (5.1) 9.6 (5.4)
Sleep efficiency (%) 82.4 (10.9) 82.0 (12.0) 82.0 (12.1) 81.4 (11.2)
Wake after sleep onset (min) 66.6 (43.9) 69.1 (48.5) 68.7 (50.3) 70.2 (46.5)
Stage 1 (%) 11.2 (6.4) 10.5 (5.5) 10.9 (6.1) 10.6 (6.2)
Stage 2 (%) 59.3 (9.8) 58.8 (11.2) 58.8 (10.1) 57.7 (11.2)
Stage 3/4 (%) 10.6 (9.0) 10.3 (9.0) 10.8 (9.6) 10.9 (10.2)
REM (%) 18.9 (6.9) 19.8 (7.1) 19.5 (7.2) 20.7 (8.0)
REM Rapid eye movement
a No significant differences between baseline and final visit were observed.
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responders to armodafinil and placebo was 71 and 53%,
respectively, in one study [26] and 72 and 37%, respectively,
in the other study [27].
Cognitive impairment is common in patients with OSA
[17]. Although the etiology has not been definitively
determined, decreased cortical activity because of impaired
arousal or neuronal damage because of chronic intermittent
hypoxia are possible causes [16, 39–41]. It is not yet clear
what additional interventions may be effective in restoring
cognitive function in patients with OSA. Findings from
studies evaluating the effects of nCPAP therapy on memory
and attention have yielded inconsistent results [15, 16, 40,
42, 43]. Unlike the findings from the individual armodafinil
OSA studies [26, 27], the pooled analysis showed that
adjunct armodafinil significantly improves long-term mem-
ory (i.e., quality of episodic secondary memory) at all study
visits compared with placebo, indicating that treatment was
associated with a greater ability to recall verbal and visual
information. Interestingly, the long-term memory benefit
occurred independent of a consistent benefit on attention
and concentration. It is important to note that the CDR
composite factors in both of the individual armodafinil
OSA studies were secondary efficacy variables. Thus,
although results from the pooled analysis provide a more
precise estimate of the effects on long-term memory, further
studies are needed to determine the potential role of
armodafinil in improving cognitive function in nCPAP-
adherent patients with OSA and associated ES.
Armodafinil significantly improved patients’ ability to
engage in activities of daily living at all visits as measured
by the ESS. The patient population studied in this pooled
analysis had severe ES (mean ESS score greater than 15)
despite effective and regular nCPAP therapy. At the final
visit, 49 and 26% of patients receiving armodafinil and
placebo, respectively, had ESS scores less than 10,
indicating that nearly half of patients no longer had
pathological sleepiness with adjunct armodafinil treatment.
Fatigue may be the presenting complaint of patients with
ES [44] and is a common associated symptom [45, 46].
Armodafinil significantly reduced fatigue, a result similar to
findings from the individual studies [26, 27]. Armodafinil
reduced global fatigue from a baseline value of 4.8 to a final
visit value of 3.6. Similarly, worst fatigue in the past 24 h was
reduced from a baseline of 7.2 to 5.8 at final visit. These
findings indicate that armodafinil significantly reduced the
severity of global fatigue andworst fatigue in the past 24 h to the
mild-to-moderate range of fatigue (BFI score less than 7 [37]).
This pooled analysis shows that armodafinil does not
adversely affect nighttime sleep in patients with OSA even
with its longer-lasting duration of action compared with
modafinil on a milligram-to-milligram basis [24]. Armodafinil
was well tolerated; in general, adverse events were rated as
mild to moderate in nature, although some patients discon-
tinued because of adverse events. There were some minor
changes in vital signs; however, these effects were not
considered to be clinically significant. The patient population
selected for both studies was verified to be adherent to
nCPAP therapy; thus, the primary pathology of OSA was
being treated in an appropriate and effective manner
throughout the course of the two studies. At the final visit,
the duration of nCPAP use had decreased minimally from
baseline compared with placebo. Average nCPAP use
remained high (approximately 7 h/night) and was effective
(i.e., low AHI values). Adjunct armodafinil treatment did not
affect arousals.
Findings from the present pooled analysis are limited to
patients with OSA who have residual ES despite regular
and effective nCPAP therapy and should not be generalized
to patients with OSA who are not receiving adequate
nCPAP therapy or are not using it regularly. Additionally,
the 12-week duration of treatment in these studies limits the
applicability of observed results to a longer period of
treatment. It should be recognized that armodafinil does not
treat the underlying airway obstruction and should not be
considered a replacement for nCPAP therapy in patients
with OSA. Further research is needed to determine the role
armodafinil may have in improving cognitive function and
whether the significant reduction in fatigue observed in the
pooled analysis will contribute toward improved quality of
life in this patient population.
In conclusion, pooled data from two 12-week, double-
blind, placebo-controlled studies showed that once-daily
administration of armodafinil significantly improved wake-
fulness when used as adjunct therapy in nCPAP-adherent
patients with residual ES associated with OSA. The effect
on wakefulness with armodafinil was maintained throughout
the day. Importantly, adjunctive treatment with armodafinil
was associated with significant improvements in long-term
memory and patients’ ability to engage in daily activities.
Armodafinil significantly reduced fatigue in the studied
population and was well tolerated.
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